Section D — Coach Move — Clinical Exercise Physiology and Exercise Medicine
This section covers the Master's chapter on Clinical Exercise Physiology and Exercise Medicine, Lessons 1 through 5: Exercise Oncology and Clinical Exercise Translation, Sports Cardiology and Exercise Cardiology, Exercise Medicine Across Populations and MoTrPAC Translation, RED-S and Eating Disorder Clinical Translation, and PEDs and the Exercise-as-Supplement Wellness-Industry Gap. All material is already in the chapter — no new content.
Part A — Vocabulary (20 points, 2 points each)
Select the single best answer for each question.
1. Morris 1953 London transport worker study (foundational anchor) demonstrated:
A) A pharmacology effect B) Bus conductors (active, climbing stairs through double-decker buses) had lower coronary heart disease incidence than bus drivers (sedentary) in the same employment population; foundational epidemiologic study establishing physical activity as cardiovascular protective at population scale; the field-founding moment of exercise epidemiology C) Sleep effects D) Diet effects
2. Exercise oncology at intervention research depth:
A) Has no clinical relevance B) Exercise as adjunct cancer therapy with intervention research at increasing methodological depth — Schmitz 2010 ACSM roundtable, ESMO 2020 guidelines, Cormie 2017 framework on exercise and cancer survivorship; effects on quality of life, fatigue, functional capacity, and emerging signal for treatment tolerance and survival in selected populations C) Has been definitively rejected D) Applies only to breast cancer
3. MoTrPAC consortium is:
A) A drug trial B) The Molecular Transducers of Physical Activity Consortium — NIH Common Fund initiative mapping the molecular responses to exercise across tissues, intensities, sex, age in human and rodent models; systems-biology framework for exercise pleiotropy at molecular signaling level; cross-references Brain Master's L2 translational neuroscience methodology C) A nutritional study D) Has been superseded
4. Female Athlete Triad → RED-S (Mountjoy 2014/2018/2023 IOC consensus):
A) Applies only to female athletes B) IOC consensus framework expanding the Female Athlete Triad (low energy availability, menstrual dysfunction, low bone mineral density) to RED-S (Relative Energy Deficiency in Sport) — extends across genders and multiple body systems (reproductive, bone, cardiovascular, GI, immune, mood, growth, performance, hematological); Loucks energy availability framework as quantitative substrate C) Has been superseded D) Applies only to elite
5. Exercise-induced atrial fibrillation in endurance athletes:
A) Is unusual B) The endurance athlete arrhythmia paradox — long-term endurance training increases atrial fibrillation incidence (Karjalainen 1998, Aizer 2009 Physicians' Health Study, Mont 2017 EHJ); J-shaped dose-response between exercise dose and AF risk; sports cardiology evaluation framework for masters endurance athletes; clinical management at population-specific depth C) Has been superseded D) Is unrelated to volume
6. Schuch 2016 versus Cooney 2013 exercise-for-depression meta-analyses:
A) Agree on effect size B) Schuch 2016 meta-analysis — adjusted for publication bias, demonstrated moderate-to-large antidepressant effect of exercise; Cooney 2013 Cochrane review — emphasized methodological concerns and smaller adjusted effects; contrast informs the methodological-evidence-threshold framework for treatment-landscape positioning of exercise within established depression treatment; cross-reference Brain Master's L1 C) Are obsolete D) Use the same methodology
7. Sports cardiology ECG criteria:
A) Are standardized internationally B) International criteria (Sharma, Drezner 2017 — refining earlier ESC and Seattle criteria) — distinguishing normal athletic adaptation ECG findings from pathologic findings warranting further evaluation; foundational for pre-participation cardiovascular screening clinical practice C) Are obsolete D) Apply only to professional athletes
8. Pope 2014 Endocrine Society statement on PED harms:
A) Was unrelated to medicine B) Endocrine Society consensus on anabolic-androgenic steroid harms — cardiovascular (dyslipidemia, LV hypertrophy, atherothrombotic risk, cardiomyopathy), endocrine (HPG suppression, infertility, testicular atrophy), hepatic (17α-alkylated oral steroids), psychiatric (mood disorder, aggression, depression at supraphysiological doses; dependence and withdrawal); foundational framework for PED harms at clinical translational depth C) Has been superseded D) Endorsed PED use
9. CTE post-mortem diagnostic limitation (cross-reference Brain Master's L3):
A) Is fully resolved B) CTE is currently diagnosable only post-mortem via specific tau pathology distribution at NINDS criteria depth; ante-mortem clinical diagnostic criteria (TES) are research framework not validated clinical diagnostic standard; epidemiologic studies in deceased contact-sport athletes show high CTE prevalence with selection bias caveats; youth football policy debates operate under this diagnostic uncertainty C) Is fully diagnosable in life D) Has been superseded
10. Gender-affirming hormone therapy distinct from PED use:
A) Is identical to PED use B) Gender-affirming hormone therapy at physiologic replacement doses (informed by Endocrine Society 2017 clinical practice guideline and WPATH Standards of Care 8) is medical care under endocrinology direction; methodologically and ethically distinct from supraphysiological PED use; conflating the two is a documented public-discourse confusion that the Master's chapter explicitly addresses C) Is unrelated to medicine D) Has been superseded
Part B — Concept Comprehension (20 points, 2 points each)
Select the single best answer for each question.
11. Exercise as cardiometabolic intervention at Master's translational depth:
A) Lacks intervention research B) Look AHEAD trial (Wing 2013 NEJM) — intensive lifestyle intervention including substantial physical activity in type 2 diabetes did not reduce cardiovascular events despite weight loss and glycemic improvement; informs the careful framing of exercise cardiovascular benefit at population intervention scale; substantial subsequent intervention research at intermediate-endpoint scale supports cardiometabolic benefit framework C) Has been superseded D) Applies only to elite athletes
12. Anomalous coronary arteries in sports cardiology:
A) Are unrelated to SCD B) Are a recognized cause of sudden cardiac death in young athletes — often clinically silent before the event; ECG often normal at rest; cardiac MR or coronary CT angiography may be diagnostic; one of the principal SCD differentials in young athletes alongside HCM, ARVC, channelopathies C) Are always symptomatic D) Have been superseded
13. Hypertrophic cardiomyopathy (HCM) in athlete population at Master's depth:
A) Has no screening implication B) The most common cause of SCD in young athletes in many U.S. cohort series — Maron registry framework; pre-participation cardiovascular screening and ECG criteria for HCM recognition; athletic-heart-versus-HCM differential (LV wall thickness, family history, genetic testing); restriction-versus-clearance frameworks have evolved (2015 AHA/ACC guideline more permissive than historical 2005 Bethesda Conference framework) C) Has been superseded D) Applies only to elderly
14. Concurrent training interference at Master's depth (cross-reference Cold L2):
A) Is theoretical B) AMPK sensing elevated AMP/ATP ratio (low energy state) → AMPK phosphorylates TSC2 activating it as Rheb-GAP → Rheb-GTP to Rheb-GDP → mTORC1 inactive; endurance training in close temporal proximity to resistance training risks AMPK activation attenuating mTORC1 activation; Cold L2 covers Roberts 2015 CWI/mTORC1 attenuation as parallel mechanism; combined frame supports temporal separation and modality consideration C) Has been superseded D) Applies only to elite
15. Exercise pharmacokinetic interactions at Master's depth:
A) Are minimal B) Include altered drug distribution (increased cardiac output and tissue perfusion), altered plasma protein binding in some contexts, altered renal clearance with exercise-induced hemodynamic changes; clinically relevant for selected medications (beta-blockers attenuating exercise heart rate response, exercise-induced hypoglycemia risk with insulin/sulfonylureas, exercise-induced bronchospasm and asthma pharmacotherapy) C) Have been superseded D) Apply only to elite
16. Loucks energy availability framework (RED-S substrate):
A) Is a body composition measure B) Energy intake minus exercise energy expenditure, normalized to fat-free mass (kcal/kg FFM/day); below ~30 kcal/kg FFM/day produces substantial endocrine disruption (LH pulsatility suppression, T3 reduction, cortisol elevation, IGF-1 reduction, insulin); foundational framework for RED-S quantitative substrate; clinical implications for menstrual dysfunction, stress fracture risk, suboptimal recovery C) Has been superseded D) Applies only to research
17. Exercise as depression intervention at methodological-evidence-threshold framework:
A) Is unsupported B) The Schuch 2016 versus Cooney 2013 meta-analysis contrast informs the methodological-evidence-threshold framework — sufficient methodologically-rigorous RCT evidence positions exercise within the established depression treatment landscape (parallel to Lam 2016 JAMA Psychiatry for light therapy); cross-reference Brain Master's L1 depression treatment landscape positioning C) Has been definitively rejected D) Applies only to subclinical depression
18. PED-research-to-conditioning-industry framing gap:
A) Is undocumented B) Research literature describes effects and harms (Bhasin 1996 NEJM on supraphysiological testosterone effects on muscle mass; Pope 2014 Endocrine Society on PED harms); conditioning-industry and social-media framing often minimizes harms or describes lifestyle protocols; wellness-industry-research-gap pattern operates in PED space alongside cold-as-supplement, exercise-as-supplement, and other wellness-industry surfaces C) Has been resolved D) Has been overstated
19. Exercise medicine across populations at Master's depth:
A) Applies one framework universally B) Population-specific exercise prescription frameworks — pediatric, adolescent, older adult, pregnancy, postpartum, chronic disease populations (cardiac rehabilitation, pulmonary rehabilitation cross-reference Breath L1, oncology rehabilitation cross-reference Move L1); ACSM Guidelines for Exercise Testing and Prescription as the U.S. clinical reference framework C) Has been superseded D) Applies only to clinical populations
20. Coach Move integrator position at Master's depth (Active Output):
A) Is abstract B) The Active Output position at Master's translational depth holds exercise oncology and clinical exercise translation (Move L1), sports cardiology with HCM/ARVC/channelopathy clinical landscape (Move L2), exercise medicine across populations and MoTrPAC translation (Move L3), RED-S and eating disorder clinical translation (Move L4), and PED-and-exercise-as-supplement wellness-industry framework (Move L5) — visible kinetic capacity now framed through clinical translational and public-health translational layers C) Same as Substrate D) Same as System Probe
Part C — Application (30 points, 6 points each)
Write 5-7 complete sentences with specific reference to chapter content, primary literature citations, and methodological framings where asked.
21. Morris 1953 London transport workers and the field-founding of exercise epidemiology. Walk the Morris 1953 study design (bus conductor versus bus driver coronary heart disease incidence comparison within same employment population) and findings. Articulate why this is the field-founding moment of exercise epidemiology and how it anchored the Master's chapter. Position Morris 1953 alongside Appel 1997 (Food), Zarate 2006 (Brain), Spielman 1986 (Sleep), Nielsen 2013 (Cold), Casa 2007 (Hot), ARDSNet 2000 (Breath), Lam 2016 (Light), and Heerspink 2020 (Water) as Master's clinical-translational anchors.
22. Schuch 2016 vs Cooney 2013 meta-analyses and the methodological-evidence-threshold framework. Walk the Schuch 2016 versus Cooney 2013 contrast on exercise for depression — Schuch's publication-bias-adjusted finding of moderate-to-large effect size versus Cooney's emphasis on methodological concerns and smaller adjusted effects. Explain the methodological-evidence-threshold framework for treatment-landscape positioning at Master's depth — what evidence threshold currently positions exercise WITHIN established depression treatment landscape (parallel to Lam 2016 JAMA Psychiatry for light therapy in non-seasonal MDD)? Cross-reference Brain Master's Lesson 1 depression treatment landscape.
23. RED-S clinical recognition with eating disorder vigilance. A graduate-program endurance athlete shows recent stress fracture history, menstrual irregularity (or in male athletes, low libido and reduced morning erections), suboptimal recovery, mood symptoms, and food rigidity. Walk the Loucks energy availability framework as RED-S quantitative substrate (energy intake minus exercise energy expenditure normalized to fat-free mass; below ~30 kcal/kg FFM/day endocrine disruption threshold). Apply the Mountjoy 2014/2018/2023 IOC RED-S framework across multiple body systems. Name verified currently-active crisis resources: 988 (call or text 988, 24/7), Crisis Text Line (text HOME to 741741, 24/7), National Alliance for Eating Disorders (866-662-1235, weekdays 9am-7pm Eastern), SAMHSA National Helpline (1-800-662-4357, 24/7). Identify the older NEDA helpline (1-800-931-2237) as non-functional.
24. Sports cardiology safety surface in young athletes. A college-aged athlete presents with exertional syncope during practice. Walk the sports cardiology differential at Master's depth — HCM (most common SCD cause in young U.S. athletes per Maron registry), ARVC, anomalous coronary arteries (often clinically silent), inherited channelopathies (LQT1, LQT2, LQT3, Brugada, CPVT). State the diagnostic pathway (history, family history, ECG with international criteria interpretation, echocardiogram, possibly cardiac MR/CT angiography, possibly genetic testing). Apply the descriptive-not-diagnostic framing — clinical decisions belong in sports cardiology hands; restriction from competition pending evaluation is standard.
25. PED harms and gender-affirming hormone therapy distinction at Master's depth. Walk the Pope 2014 Endocrine Society statement on PED harms framework — cardiovascular, endocrine, hepatic (for 17α-alkylated oral steroids), and psychiatric harms at supraphysiological doses. Distinguish PED use (supraphysiological doses, outside medical care, without comprehensive monitoring) from gender-affirming hormone therapy (physiologic replacement doses under endocrinology direction, informed by Endocrine Society 2017 clinical practice guideline and WPATH Standards of Care 8). Apply the wellness-industry-research-gap pattern to the conditioning-industry framing of PED use that minimizes harms. Why does the Master's chapter explicitly address this distinction?
Continue to Section E — Coach Cold.